尽管有部分资产被剥离,但阿伯维报告说财务状况强,并吸引了新的投资者,并获得"中等购买"评级. Despite some divestment, AbbVie reports strong financials and attracts new investors, with a "Moderate Buy" rating.

美国主要制药公司AbbVie Inc.在四季度的业绩不佳, 卡罗莱纳财富咨询公司的股份减少了3.4%, 但受到REAP金融集团和Heck Capital Advisors等新机构投资者的关注. AbbVie Inc., a major pharmaceutical company, saw a mixed quarter with Carolinas Wealth Consulting reducing its holdings by 3.4%, but gaining interest from new institutional investors like REAP Financial Group and Heck Capital Advisors. AbbVie报告说,EPS为2.46美元,超过预期,分析家预测该年的EPS为12.31美元。 AbbVie reported a strong $2.46 EPS, surpassing expectations, and analysts predict a 12.31 EPS for the year. 该库存目前为183.26美元,其协商一致目标为210.53美元,评级为“中价购买”。 The stock, currently at $183.26, has a consensus target of $210.53 with a "Moderate Buy" rating. 尽管内幕出售,但AbbVie稳健的金融业务和多样化的处理投资组合继续吸引投资者。 Despite insider selling, AbbVie's robust financials and diversified treatment portfolio continue to attract investors.